Galena Biopharma has reported a net loss of $6.26m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net loss of $5.47m, or $0.09 per share, for the third quarter ended 30 September 2011. Operating loss for ...
Tags: Net Loss, operational and business development, patient enrollment